A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Have bronchiectasis due to CF, hypogammaglobulinemia, common variable immunodeficiency, known active nontuberculous mycobacteria (NTM) lung infection, or pulmonary fibrosis.
• •Known or suspected immunodeficiency disorder.
• •Pulmonary exacerbation which has not resolved clinically during screening period.
• •Have significant haemoptysis.
• •Have any clinically significant abnormal laboratory values at Screening or diseases or disorders.
• •History of lung transplantation.
• •History of malignancy within 5 years before Screening, or during the screening period
• •Currently being treated with antimicrobial therapy for tuberculosis (TB).
• •Currently on active treatment for allergic bronchopulmonary aspergillosis (ABPA).
• •Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease
• •Known allergy to itepekimab or to excipients
• •Live-attenuated vaccine(s) within 4 weeks prior to Screening or plans to receive such vaccines during the study
• •Unstable ischemic heart disease
• •Cardiomyopathy or other relevant cardiovascular disorder
• •Clinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening
• •History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Screening.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.